Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meloxicam Nanocrystal Injection PK and Safety in Healthy Subjects
NCT06902090Phase 1Completed
- Sponsor
- Yangtze River Pharmaceutical Group
- Start
- Jul 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of meloxicam in pain (2 arms), sponsored by Yangtze River Pharmaceutical Group. Primary endpoints: Maximum drug plasma concentration up to 96 hours, Time to achieve Cmax up to 96 hours and 8 more. Started Jul 2023; status: completed.
02
Drugs
meloxicam
03
Conditions
pain
Beyond the preview
Go deeper on NCT06902090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06902090.